| Today’s Big NewsJun 25, 2025 |
| By Nick Paul Taylor Kymera Therapeutics sweetened news of a setback Wednesday, revealing that Sanofi is pulling back from its lead IRAK4 degrader alongside details of the selection of a follow-up prospect and a $750 million deal with Gilead. |
|
|
|
By James Waldron Biogen has pointed to an early readout from a small phase 1 trial as evidence that its antisense oligonucleotide salanersen could help children with spinal muscular atrophy (SMA) who are still struggling to sit independently despite having received Novartis’ Zolgensma. |
By Gabrielle Masson While the IPO landscape remains icy, Minovia Therapeutics is skating into the market using a special purpose acquisition company (SPAC) road. |
By James Waldron Bayer-owned BlueRock Therapeutics is laying off 50 employees and shuttering its research labs in Cambridge, Mass., in order to focus its resources on its priority cell therapies, a spokesperson said. |
|
Immune cell engagers are opening new avenues in immuno-oncology. Discover how single-cell analysis is enabling smarter, faster ICE discovery. Watch now
|
|
By Angus Liu In one of the first major tests of the new FDA leadership’s regulatory philosophy toward gene therapies for rare diseases, the agency is investigating two Duchenne muscular dystrophy patient deaths following treatment with Sarepta Therapeutics’ Elevidys. |
By James Waldron Arbutus had made no secret of its desire to step up its plans for imdusiran. Now, the company has regained the China rights to the potential functional cure for hepatitis B. |
By Gabrielle Masson Sangamo Therapeutics’ investigational gene therapy appears to improve kidney function at 52 weeks for patients with a rare genetic disorder. |
By Heather Landi HHS Secretary Robert F. Kennedy Jr. defended his reorganization of the agency and the proposed fiscal 2026 budget that cuts funding by 25% during a hearing Tuesday of the House Energy and Commerce Health subcommittee. |
By Nick Paul Taylor Novo Nordisk is under fire over a Spanish obesity awareness campaign. After the campaign stirred up controversy, the Spanish ministry of health wrote to the drugmaker about a possible violation of drug advertising regulations. |
By Kevin Dunleavy Two months after Bristol Myers Squibb fended off a lawsuit which accused the drugmaker of using illegal tactics to protect its monopoly on multiple myeloma medicine Pomalyst, BMS is back in court, facing similar allegations from insurance giant Cigna over its strategy with the same treatment. |
Fierce podcastsDon’t miss an episode |
| | This week on "The Top Line," AbbVie’s Daejin Abidoye, M.D., joins us to discuss the future of antibody drug conjugates. |
|
|---|
|
|
|
Thursday, July 10, 2025 | 10am ET / 7am PT The transition from drug discovery to process development poses significant challenges. Join us for this deep dive into how adopting a collaborative approach between medicinal and process chemistry teams can help address key obstacles and accelerate progress from discovery to early clinical milestones. Register now.
|
|
| Executive SummaryBiotech innovation doesn’t slow down—and neither should your lab partner. This brief outlines how early scientific engagement, operational transparency, and integrated global lab services help reduce risk, stay on schedule, and deliver results. Whether you're navigating your first trial or scaling a growing pipeline, see how a purpose-built lab model can help you move smarter and faster. Sponsored by: IQVIA Laboratories |
| WhitepaperWe analyzed ~300 launches to identify the factors most correlated with commercial success & built a framework for peak go-to-market performance. Presented by Blue Matter, strategic consultants in the life sciences |
| |
|
